GLMD — Galmed Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $5.75m
- -$13.30m
- 23
- 55
- 49
- 37
Annual income statement for Galmed Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 30.2 | 32.9 | 17.7 | 7.49 | 7.42 |
| Operating Profit | -30.2 | -32.9 | -17.7 | -7.49 | -7.42 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -28.8 | -32.5 | -17.9 | -6.91 | -7.52 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -28.8 | -32.5 | -17.9 | -6.91 | -7.52 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -28.8 | -32.5 | -17.9 | -6.91 | -7.52 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -28.8 | -32.5 | -17.9 | -6.91 | -7.52 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -243 | -238 | -128 | -29.9 | -6.85 |